CCL11型
免疫学
特应性皮炎
趋化因子
嗜酸性粒细胞
炎症
嗜酸性粒细胞趋化因子
生物
免疫系统
成纤维细胞
细胞生物学
医学
细胞培养
哮喘
遗传学
作者
Kang I. Ko,Jean Merlet,Brett P. DerGarabedian,Zhen Huang,Yoko Suzuki‐Horiuchi,Matthew L. Hedberg,Eileen Hu,Anh Nguyen,Stephen M. Prouty,Faizan Alawi,Matthew C. Walsh,Yongwon Choi,Sarah E. Millar,Ashley Cliff,Jonathon Romero,Michael R. Garvin,John T. Seykora,Daniel Jacobson,Dana T. Graves
出处
期刊:Science Translational Medicine
[American Association for the Advancement of Science (AAAS)]
日期:2022-02-02
卷期号:14 (630)
被引量:25
标识
DOI:10.1126/scitranslmed.abj0324
摘要
Skin is composed of diverse cell populations that cooperatively maintain homeostasis. Up-regulation of the nuclear factor κB (NF-κB) pathway may lead to the development of chronic inflammatory disorders of the skin, but its role during the early events remains unclear. Through analysis of single-cell RNA sequencing data via iterative random forest leave one out prediction, an explainable artificial intelligence method, we identified an immunoregulatory role for a unique paired related homeobox-1 (Prx1)+ fibroblast subpopulation. Disruption of Ikkb-NF-κB under homeostatic conditions in these fibroblasts paradoxically induced skin inflammation due to the overexpression of C-C motif chemokine ligand 11 (CCL11; or eotaxin-1) characterized by eosinophil infiltration and a subsequent TH2 immune response. Because the inflammatory phenotype resembled that seen in human atopic dermatitis (AD), we examined human AD skin samples and found that human AD fibroblasts also overexpressed CCL11 and that perturbation of Ikkb-NF-κB in primary human dermal fibroblasts up-regulated CCL11. Monoclonal antibody treatment against CCL11 was effective in reducing the eosinophilia and TH2 inflammation in a mouse model. Together, the murine model and human AD specimens point to dysregulated Prx1+ fibroblasts as a previously unrecognized etiologic factor that may contribute to the pathogenesis of AD and suggest that targeting CCL11 may be a way to treat AD-like skin lesions.
科研通智能强力驱动
Strongly Powered by AbleSci AI